Drug
Pegaptanib clinical trials
- studies test it
- 33
- open now
- 0
- in phase 3
- 9
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
33 studies that test it; most in 2006 (10)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 10 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 11
- Phase 3
- 9
- Phase 4
- 10
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 15
Eyetech Pharmaceuticals (10) · Pfizer (7) · Valley Retina Institute (2) · Johns Hopkins University (2) · Wake Forest University (1) · Bausch & Lomb Incorporated (1) · Palmetto Retina Center, LLC (1) · London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's (1)
Often tested with
Tested in the same studies.
Verteporfin (2) · Bevacizumab (1) · Ranibizumab (1) · Aflibercept (1)
Studies
Open first, then newest update. How each study uses pegaptanib is read from its arms, and is right about nine times in ten.
Testing it · 33
- Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular EdemaCompletedNot applicableWake Forest UniversityNCT00790803Written as Pegaptanib
- Extension Study to Gather Data on Effect of Macugen on the Corneal EndotheliumCompletedPhase 4Bausch & Lomb IncorporatedNCT01573572Written as pegaptanib sodium injection
- A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.CompletedPhase 2/3PfizerNCT00605280Written as Macugen
- Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownPhase 4Kagawa UniversityNCT02321267Written as ranibizumab, aflibercept, pegaptanib, verteporphin
- Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic MyopiaWithdrawnNot applicableL.V. Prasad Eye InstituteNCT01218230Written as Intravitreal Pegaptanib
- Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein OcclusionCompletedPhase 4Palmetto Retina Center, LLCNCT00406107Written as pegaptanib sodium (Macugen)
- A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic RetinopathyWithdrawnPhase 3Greater Houston Retina ResearchNCT01589718Written as Macugen
- Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular EdemaCompletedPhase 3PfizerNCT01189461Written as pegaptanib sodium
- A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular EdemaCompletedPhase 3PfizerNCT01100307Written as pegaptanib sodium
- Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) StudyCompletedPhase 4Valley Retina InstituteNCT01486238Written as Macugen® pegaptanib sodium
- Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)CompletedNot applicableLondon Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph'sNCT00446381Written as Macugen (pegaptanib)
- An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMDTerminatedPhase 4PfizerNCT00327470Written as Pegaptanib Sodium 0.3 mg
- A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic RetinopathyCompletedPhase 1Retina Institute of HawaiiNCT01487070Written as Macugen (Pegaptanib Sodium)
- Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)Status unknownPhase 4Valley Retina InstituteNCT01486771Written as Macugen ® (pegaptanib sodium)
- Subretinal Macugen® for Neovascular Age-Related Macular DegenerationStatus unknownPhase 3Klinikum LudwigshafenNCT00788177Written as Pegaptanib (Macugen®)
- Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular DegenerationCompletedPhase 2PfizerNCT00239928Written as pegaptanib sodium
- Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration LesionsCompletedPhase 4PfizerNCT00324116Written as pegaptanib sodium (Macugen)
- MAAM Study: Avastin and Macugen Versus Avastin Versus MacugenCompletedPhase 2The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser SurgeryNCT00531336Written as Pegaptanib (Macugen)
- The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular EdemaTerminatedPhase 1/2Johns Hopkins UniversityNCT00358423Written as Pegaptanib Sodium
- Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in DiabeticsTerminatedPhase 1/2Johns Hopkins UniversityNCT00346983Written as Pegaptanib sodium
See all 33 studies that test pegaptanib →
As the comparator · 1 — what is tested is compared with pegaptanib
Codes
What other systems call pegaptanib · ClinicalTrials.gg INT004731
- MeSH (NLM) C495058pegaptanibOne source NLM
- UNII (FDA) 2H1PA8H1ENPEGAPTANIBConfirmed FDA, NLM
- RxNorm 498509One source FDA
- NCI Thesaurus C90657PegaptanibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C495058 | pegaptanib | One source NLM |
| UNII (FDA) | 2H1PA8H1EN | PEGAPTANIB | Confirmed FDA, NLM |
| RxNorm | 498509 | — | One source FDA |
| NCI Thesaurus | C90657 | Pegaptanib | One source FDA |
Also registered as pegaptanib sodium (UNII 3HP012Q0FH · RxNorm 594119).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.